These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27709685)

  • 1. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
    Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
    Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.
    Jabbari E; Koga S; Valentino RR; Reynolds RH; Ferrari R; Tan MMX; Rowe JB; Dalgard CL; Scholz SW; Dickson DW; Warner TT; Revesz T; Höglinger GU; Ross OA; Ryten M; Hardy J; Shoai M; Morris HR;
    Lancet Neurol; 2021 Feb; 20(2):107-116. PubMed ID: 33341150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of LRRK2 in tauopathies.
    Herbst S; Lewis PA; Morris HR
    Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.
    Madzar D; Schulte C; Gasser T
    Eur J Neurol; 2009 Nov; 16(11):1230-2. PubMed ID: 19538213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lrrk2 R1441 substitution and progressive supranuclear palsy.
    Ross OA; Whittle AJ; Cobb SA; Hulihan MM; Lincoln SJ; Toft M; Farrer MJ; Dickson DW
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):23-5. PubMed ID: 16409550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
    Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
    J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
    J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 variation and dementia with Lewy bodies.
    Heckman MG; Soto-Ortolaza AI; Contreras MYS; Murray ME; Pedraza O; Diehl NN; Walton R; Labbé C; Lorenzo-Betancor O; Uitti RJ; van Gerpen J; Ertekin-Taner N; Smith GE; Kantarci K; Savica R; Jones DT; Graff-Radford J; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Parisi JE; Rademakers R; Wszolek ZK; Graff-Radford NR; Ferman TJ; Dickson DW; Boeve BF; Ross OA
    Parkinsonism Relat Disord; 2016 Oct; 31():98-103. PubMed ID: 27521182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy.
    Tuite PJ; Clark HB; Bergeron C; Bower M; St George-Hyslop P; Mateva V; Anderson J; Knopman DS
    Arch Neurol; 2005 Sep; 62(9):1453-7. PubMed ID: 16157754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.
    Koga S; Kouri N; Walton RL; Ebbert MTW; Josephs KA; Litvan I; Graff-Radford N; Ahlskog JE; Uitti RJ; van Gerpen JA; Boeve BF; Parks A; Ross OA; Dickson DW
    Acta Neuropathol; 2018 Sep; 136(3):389-404. PubMed ID: 29926172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of variants of progressive supranuclear palsy.
    Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
    Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration.
    Schofield EC; Caine D; Kril JJ; Cordato NJ; Halliday GM
    Mov Disord; 2005 Jan; 20(1):34-9. PubMed ID: 15390131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Respondek G; Grimm MJ; Piot I; Arzberger T; Compta Y; Englund E; Ferguson LW; Gelpi E; Roeber S; Giese A; Grossman M; Irwin DJ; Meissner WG; Nilsson C; Pantelyat A; Rajput A; van Swieten JC; Troakes C; Höglinger GU;
    Mov Disord; 2020 Jan; 35(1):171-176. PubMed ID: 31571273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.
    Sandberg A; Ling H; Gearing M; Dombroski B; Cantwell L; R'Bibo L; Levey A; Schellenberg GD; Hardy J; Wood N; Fernius J; Nyström S; Svensson S; Thor S; Hammarström P; Revesz T; Mok KY
    Neurobiol Dis; 2020 Dec; 146():105079. PubMed ID: 32961270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration.
    Higgins JJ; Litvan I; Nee LE; Loveless JM
    Neurology; 1999 Jan; 52(2):404-6. PubMed ID: 9932968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Coughlin DG; Dickson DW; Josephs KA; Litvan I
    Adv Exp Med Biol; 2021; 1281():151-176. PubMed ID: 33433875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.